# A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

> **NCT07636811** · PHASE2 · RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 58 (estimated)

## Conditions studied

- Down Syndrome-Associated Alzheimer's Disease (DS-AD)

## Interventions

- **DRUG:** Mivelsiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07636811
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-17
- **Primary completion:** 2030-05-18
- **Final completion:** 2031-07-23
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636811, "A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07636811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*